Table 3.
Compound | IC50 (µg/mL)a,b,c | ||
---|---|---|---|
HepG2 | A549 | HCC-S102 | |
PC | 23.0 ± 1.4 | 19.0 ± 1.4 | 18.0 ± 1.4 |
PE | >50 | >50 | >50 |
C2 | >50 | >50 | >50 |
C3 | 15.0 ± 4.2 | 6.0 ± 2.8 | 11.0 ± 1.4 |
C4 | 15.0 ± 0.0 | 10.7 ± 3.3 | 14.5 ± 2.1 |
C5 | 7.0 ± 2.5 | 14.5 ± 3.5 | 8.5 ± 0.7 |
C6 | 15.0 ± 1.4 | 22.5 ± 0.7 | 17.5 ± 2.1 |
C7 | 22.0 ± 7.1 | 34.5 ± 2.1 | 25.0 ± 2.8 |
C8 | 14.5 ± 4.9 | 17.5 ± 4.9 | 17.0 ± 1.4 |
C9 | 9.3 ± 6.6 | 6.75 ± 0.4 | 10.6 ± 1.4 |
E3.6 | 12.5 ± 0.7 | 18.0 ± 0.0 | 16.0 ± 1.4 |
E4 | >50 | >50 | >50 |
E5 | 40.5 ± 7.8 | >50 | 45.0 ± 7.1 |
Etoposide | 0.20 | 0.34 | 0.32 |
a Cell lines are: HepG2 Human hepatocellular liver carcinoma cell line; A549 Human lung carcinoma cell line; HCC-S102 Hepatocellular carcinoma cell line.
b When IC50 > 50 μg/mL denotes inactive cytotoxic activity.
c The assays were performed in triplicate using etoposide as the reference drug.